| Bioactivity | DCZ0415, a potent TRIP13 inhibitor, impairs nonhomologous end joining repair and inhibits NF-κB activity. DCZ0415 induces anti-myeloma activity in vitro, in vivo, and in primary cells derived from drug-resistant myeloma patients[1]. | ||||||||||||
| Invitro | DCZ0415 (10, 20 μM; 72 hours) shows a significant decrease in colony formation, indicating it inhibits cell proliferation[1]. DCZ0415 (1.25-40 μM; 72 hours) induces a significant dose-dependent decrease of viability inMM cells[1]. DCZ0415 (10, 20 μM; 24-72 hours) shows a dose-dependent relationship between DCZ0415 treatment and apoptotic cell death[1]. DCZ0415 (10, 20 μM; 24 hours) induces a significant accumulation in G0/G1 MM cells[1]. DCZ0415 (10 μM; 48 hours) decreases the protein levels of phosphorylated (p)-iκBα and phosphorylated (p)-NF-κB in MM cells[1]. DCZ0415 has IC50s of 1.0–10 μM in CalcuSyn in MM cell lines[1]. DCZ0415 exerts cytotoxic effects by inhibiting DNA 288 synthesis in MM cells[1]. Cell Proliferation Assay[1] Cell Line: | ||||||||||||
| Name | DCZ0415 | ||||||||||||
| CAS | 2242470-43-3 | ||||||||||||
| Formula | C23H20N2O2 | ||||||||||||
| Molar Mass | 356.42 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|